New York, NY -- (SBWIRE) -- 12/19/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Allied Nevada Gold Corp (NYSEMKT:ANV), Delcath Systems, Inc (NASDAQ:DCTH), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Orexigen Therapeutics, Inc (NASDAQ:OREX)
Allied Nevada Gold Corp (NYSEMKT:ANV) showed a volume of 3.80 million shares by the end of last trade whereas the average volume of the stock remained 3.58 million shares. The stock opened the session at $3.31 but then moved to $3.25. At that price, the stock showed a negative performance of 1.52%. Allied Nevada Gold Corp. (Allied Nevada) is a gold and silver producer focused on mining, development, and exploration of properties in the state of Nevada. The Company’s operating mine, the Hycroft Mine, is an open-pit gold and silver heap leach operation located 54 miles west of Winnemucca, Nevada. During the year ended December 31, 2012, the Hycroft Mine produced 136,930 ounces of gold and 794,097 ounces of silver. In addition to the Hycroft Mine,
Will ANV Get Buyers Even After The Recent Rally? Find Out Here
Delcath Systems, Inc (NASDAQ:DCTH) opened the session at $0.25 and closed the session at $0.235. The stock showed a negative performance of -6.00% in previous trading session. Traded with volume of 3.78 million shares in the prior session and the average volume of the stock remained 1.56 million shares. Delcath Systems, Inc. (Delcath) is a development-stage, specialty pharmaceutical and medical device company, focused on oncology, initially cancers in the liver. Delcath focuses on the development and clinical study of the Delcath chemosaturation system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. Once the organ is isolated, the Delcath chemosaturation system delivers doses of chemotherapeutic agents directly to the liver.
Has DCTH Found The Bottom And Ready To Gain Momentum? Find Out Here
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) opened the session at $2.67 and closed the session at $2.65. The stock showed a negative performance of -1.12% in previous trading session. Traded with volume of 3.78 million shares in the prior session and the average volume of the stock remained 2.54 million shares. The beta of the stock remained 1.38. AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare,
Why Should Investors Buy AVNR After the Recent Fall? Just Go Here and Find Out
Orexigen Therapeutics, Inc (NASDAQ:OREX) the stock advanced 1.49% and finished the session at $5.46. Traded with volume of 3.72 million shares in the prior session and the average volume of the stock remained 2.80 million shares. The beta of the stock remained 2.14. Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body's efforts to compensate for weight loss.
Will OREX Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)